Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxyg... (eir care in order to live in an independ...)

(Date:7/26/2008)...ents freedom of movement, better quality of life ,... An automated artificial kidney that can be worn ...at the insulin pump is to diabetes patients. , ...orks better than conventional dialysis, according ...xperimental Nephrology . , "What,s really new a...

(Date:7/25/2008)...wswire-USNewswire/ -- Anthony Shih,M.D., M.P.H., ...e President,of Strategic Planning, after a two-yea...ation committed to improving U.S. health system pe...ram on Health Care Quality,Improvement and Efficie.../20080725/DC28791LOGO ), Board-certified in publ...

(Date:7/25/2008)...troviral therapy may be due to genetic factors , ...ew study challenges the long-held belief that the ...s ability to restore itself after HIV patients are... (HAART). , From 50 percent to 90 percent of HI...Intravenous drug use is the main cause of both typ...

(Date:7/25/2008)...sumers tips and encourages them to, ,Speak Up,(TM...uly 25 /PRNewswire-USNewswire/ -- The Pennsylvania... Patient Safety Day" which,is a national effort to...ate fully in their healthcare by asking questions ...ry or illness., "We understand the important role...

Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2 Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2 Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2 Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3

[0] Automated, Wearable Kidney Offers Continuous Dialysis [0] IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead [0] Study Disproves Belief That Hepatitis C Blunts HIV Drugs [0] Patient Safety Authority Supports 'National Patient Safety Day'

...urprisingly few doctors are ‘logged’ in. For year... Internet technology and result in doctor- patie...ed. Research published in Wall Street Journal Onl...t of adults receive e-mail from their doctors. An...

...taking a break has helped a doctor here to conduct...hnique of single hole surgery. Doctor Ajay Prakas...pital in Agra at around 10 p.m. Thursday night and...ill 10 a.m. Friday morning, removing 45 gall bladd...

...f a woman’s reproductive years, usually occurs aro...men experience //early menopause. Early menopause ... of health problems, including osteoporosis and ca...ssue of Mayo Clinic Women’s HealthSource describes...

...se by nearly 22 percent between 2000 and 2004 – fr... and Numbers// from the Agency for Healthcare Rese... percent during the previous seven years. AHRQ f... every five admissions resulted from people being ...

Other Medicine News:Health News:Doctors –you’ve Got Ma 2

Doctors –you’ve Got Ma Agra Surgeon Conducts Fifty Operations at One Go Managing Early-Onset Menopause Burn Hospitalizations on the Rise

(Date:7/23/2008)... July 23 /- InCode BioPharmaceutics, ... announced preclinical test,results demonstrating ...,the treatment of the rare chronic blood disorder ...plete results will be presented at the XXII,Intern... September 28,2008., The only treatment currentl...

(Date:7/23/2008)...d on IND-Enabling Work with Protein Therapeutics t...lement System, CAMBRIDGE, Mass., July 23 /PRNewsw...it has initiated a corporate growth plan with the,...cutive officer and the,establishment of its headqu...oodruff Emlen, M.D., a co-founder of the company w...

(Date:7/22/2008)...acy results from a multi-center 293-patient Europe... Stock Exchange Symbol: CYT, MONTREAL, July 22 /P...c., the global leader in cryotherapy products to t...ults previously presented from three,European stud... Front(R),were published earlier today in the Jou...

(Date:7/22/2008)...under Therapeutics Development Initiative bring MJ... next deadline January 20,2009, NEW YORK, July 2...n to,speed delivery of transformative treatments a...Fox Foundation for Parkinson,s Research has awarde...search teams. The awards,were granted under MJFF,s...

Breaking Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2 Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2 Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3 CryoCath Arctic Front(R) Results Published in JACC 2 CryoCath Arctic Front(R) Results Published in JACC 3 Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2 Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3 Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 1 Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 2 Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 3 Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 4 Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 1 Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 2 Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 4267 3 Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 1 Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 2 Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 3 Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 4 Field Museum Launches Shared Bike Program for Employees 15487 1 Field Museum Launches Shared Bike Program for Employees 15487 2

[0] InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)[0] Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters [0] CryoCath Arctic Front(R) Results Published in JACC [0] Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics

...SINESS WIRE)--Jun 5, 2007 - NovaDel Pharma,Inc. (A...loping,oral spray formulations for a broad range o...o clinical studies comparing zolpidem,oral spray w...cokinetic (PK), pharmacodynamic (PD) and safety ob...as Ambien(R), a leading,drug for the treatment of ...

... III Study Results Presented At ASCO -- , CHICAGO ...ith,pegylated interferon alfa-2b in stage III mela...apse-free survival (RFS),according to the results...atients with stage III melanoma. Results of the Ph...r the Research and,Treatment of Cancer (EORTC) and...

Other Medicine Technology:NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 2 NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 3 NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 4 NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 5 NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 6 NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets 7 Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2 Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3 Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4 Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5

NovaDel Announces Positive Data from Two Studies Comparing Zolpidem,Oral Spray to Ambien Tablets Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival

...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...

Medicine Products:

Methyl Alcohol Methemoglobin Methemalbumin, Serum or Plasma Methane, Whole Blood

Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxyg...(eir care in order to live in an independ...),Health